SCHEMBL17614554

SCHEMBL17614554

Cc1ccc(-c2cccc(OCc3c(Cl)cccc3-n3nnn(C)c3=O)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
NPSR1 Q6W5P4 2/20 0.35
LMNA P02545 1/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
KDM4E B2RXH2 2/20 0.33
RAB9A P51151 1/20 0.33
DRD3 P35462 2/20 0.32
CSF1R P07333 1/20 0.32
TP53 P04637 1/20 0.32
GAA P10253 1/20 0.32
DRD2 P14416 1/20 0.32
CYP11B1 P15538 2/20 0.31
CYP11B2 P19099 2/20 0.31
ACP1 P24666 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16206033 0.91 SMN1; SMN2 (0.36) MAPTSMN1; SMN2KMT2AMEN1KDM4E
SCHEMBL17615238 0.90 MEN1 (0.40) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL16206095 0.90 HTR7 (0.34) MAPTSMN1; SMN2CYP11B1CYP11B2GRM2
SCHEMBL17614528 0.88 BTK (0.31) MAPTSMN1; SMN2CYP11B1CYP11B2GRM2
SCHEMBL16206004 0.86 HTR7 (0.33) MAPTKDM4ERAB9ATP53GAA
SCHEMBL17614526 0.85 HSD11B1 (0.32) CYP11B1CYP11B2HSD11B1
SCHEMBL16599409 0.84 MAPT (0.37) MAPTSMN1; SMN2KMT2AMEN1NPSR1
SCHEMBL16205996 0.83 GABRA5 (0.36) KMT2AMEN1RAB9ATP53GAA
SCHEMBL16206102 0.83 MEN1 (0.34) KMT2AMEN1KDM4ECYP11B1CYP11B2
SCHEMBL17615155 0.83 CYP3A4 (0.35) MAPTSMN1; SMN2KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9867372-B2 Tetrazolinone compound and use of same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-01-16 US disclosed
US-20160081339-A1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160081339-A1 TETRAZOLINONE COMPOUND AND USE OF SAME MT-CO1, SOD1, MT-CO2 MAPT 2738/4885SMN1; SMN2 2032/4885KMT2A 2241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.